📈 Fed's first cut since 2020: Time to buy the dip? See Tech-focused stock picksUnlock AI Picks

Iovance Biotherapeutics Inc (IOVA)

NASDAQ
Currency in USD
Disclaimer
9.84
-0.50(-4.84%)
Real-time Data
IOVA Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
9.7310.37
52 wk Range
3.2118.33
Prev. Close
10.34
Open
10.32
Day's Range
9.73-10.37
52 wk Range
3.21-18.33
Volume
2,401,037
Average Volume (3m)
7,065,721
1-Year Change
96.2%
Book Value / Share
Unlock
Fair Value
Unlock
Fair Value Upside
Unlock
IOVA Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
24.42
Upside
+148.17%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year
Show more

Iovance Biotherapeutics Inc Company Profile

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Compare IOVA to Peers and Sector

Metrics to compare
IOVA
Peers
Sector
Relationship
P/E Ratio
−6.8x−5.5x−0.6x
PEG Ratio
−0.30−0.120.00
Price/Book
3.9x2.6x2.6x
Price / LTM Sales
90.9x42.0x3.1x
Upside (Analyst Target)
132.1%185.4%55.8%
Fair Value Upside
Unlock−0.6%7.3%Unlock

FAQ

What Is the Iovance Biotherapeutics (IOVA) Stock Price Today?

The Iovance Biotherapeutics stock price today is 9.84.

What Stock Exchange Does Iovance Biotherapeutics Trade On?

Iovance Biotherapeutics is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Iovance Biotherapeutics?

The stock symbol for Iovance Biotherapeutics is "IOVA."

What Is the Iovance Biotherapeutics Market Cap?

As of today, Iovance Biotherapeutics market cap is 3.14B.

What is Iovance Biotherapeutics Earnings Per Share?

The Iovance Biotherapeutics EPS is -1.67.

What Is the Next Iovance Biotherapeutics Earnings Date?

Iovance Biotherapeutics will release its next earnings report on 05 Nov 2024.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.